Efficacy of Acotiamide in PDS type Functional Dyspepsia symptoms with and without PPI and laxative co-therapy

Journal Title: The Indian Practitioner - Year 2018, Vol 71, Issue 6

Abstract

Background: Functional Dyspepsia (FD) is a common condition presenting at the clinic of a gastroenterologist. Though the Post-prandial Distress Syndrome (PDS) type is more commonly seen in clinical practice, often the symptoms overlap with Epigastric pain or burning and sometimes even with other gastro-intestinal symptoms like constipation. Acotiamide, approved specially for meal related FD symptoms, exerts its gastro- kinetic effect by enhancing the action of acetylcholine. Evidence of its efficacy and safety are available from various randomized clinical trials. However, real-world data from its regular in-clinic use especially in patients presenting with overlapping symptoms and being prescribed other concomitant therapies, is lacking. Methodology: Data, evaluated from 314 patients through questionnaires to record patient’s perception of improvement in the presenting symptoms, as well as tolerance to treatment with acotiamide 100 mg thrice daily, across gastroenterology clinics in India, was analyzed. Results: The responder rate for treatment with acotiamide in the groups receiving only acotiamide and in those also receiving Proton Pump Inhibitor (PPI) and laxatives as concomitant therapy, for each of functional dyspepsia symptoms of post prandial fullness, upper abdominal bloating and early satiety was 72.5% and 86.5%, 68.8% and 80.2%, and, 80% and 74.1% respectively. No significant difference was seen in the number of patients achieving complete relief or significant improvement from both post prandial fullness and early satiety at final follow up between the two groups. A significant difference was seen in the number of patients who ‘significantly improved’ from epigastric bloating in the group co-prescribed a PPI or a laxative with acotiamide versus the group which was only given acotiamide. Overall a low treatment discontinuation rate of 1.3% was observed. Conclusion: This real-world study suggests that use of acotiamide is associated with improvement of mealrelated (PDS) FD symptoms with good safety profile, in patients also receiving a PPI or a laxative for other overlapping symptoms with PDS.

Authors and Affiliations

Varsha Narayanan, Shailesh Pallewar, Amit Bhargava

Keywords

Related Articles

Malignant Mixed Mullerian Tumour of Uterus

Background: Malignant mixed Mullerian tumors (MMMTs) are metaplastic carcinomas including both carcinomatous and sarcomatous elements. Case: A 65-year-old postmenopausal female presented to outpatient department with chi...

Robotic Surgery : My Perspective

Cancer is something which can leave one totally shattered. Even if it is in its initial stages, the thought of having cancer can devastate a patient and his family. Cancer if detected early is curable with the right trea...

Persistent pain at mini laparotomy tubal Ligation scar- A nightmare for patient

Mini laparotomy (minilap) is the common method of tubal ligation in developing countries and is associated with various complications like pain in abdomen, menstrual irregularities, ectopic pregnancy and pelvic inflammat...

Recurrent Episode of Priapism due to Quetiapine in a Bipolar Patient

Priapism is a rare side effect of anti-psychotics. Both typical and atypical anti-psychotics can cause priapism. Priapism means persistent and most of the times painful penile erection not associated with sexual stimulat...

Comparison of Nugent’s and Amsel’s criteria in the diagnosis of Bacterial vaginosis

Objectives: (1) To confirm clinically suspected cases of Bacterial vaginosis (BV) by Amsel’s and Nugent’s criteria. (2) To compare Amsel’s and Nugent’s criteria in the diagnosis of Bacterial vaginosis. Methods: The study...

Download PDF file
  • EP ID EP576728
  • DOI -
  • Views 76
  • Downloads 0

How To Cite

Varsha Narayanan, Shailesh Pallewar, Amit Bhargava (2018). Efficacy of Acotiamide in PDS type Functional Dyspepsia symptoms with and without PPI and laxative co-therapy. The Indian Practitioner, 71(6), 19-23. https://europub.co.uk/articles/-A-576728